SARS-CoV-2 Variants Research and Vaccines
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Vaccines and Therapeutic Developments".
Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 13556
Special Issue Editors
Interests: COVID-19 therapeutics; natural therapies; liver cancer and molecular biomarkers for COVID-19 and liver cancer
Special Issue Information
Dear Colleagues,
Over the span of more than two years since the beginning of the COVID-19 pandemic, the world has witnessed the evolution of the virus through different variants which have affected global communities in many different ways to the original virus. These variants have also caused different symptoms and differences in the make-up of the infected individuals. In addition to breakthroughs in therapeutic and preventive medicine driven by the pandemic, practices have had to adapt to new ways of medicine delivery, and researchers have toiled to chronicle the layers of social, economic, and political consequences of the pandemic.
As we await the endemicity of COVID-19, waves of new variants are producing new symptoms and making multiple treatments, which were thought to be lifesaving in their inception, obsolete. Clinical trials must anticipate the future landscape that is likely to exist when they are able to be implemented in an ever-changing patient profile and attitude towards research.
This Special Issue, which is dedicated to COVID-19 two years on, will consider submissions regarding topics such as prognostic indicators of COVID-19 infections, the global heterogeneity of patients affected by local variants of the SARS-CoV2 virus, the evolving approaches to diagnosis, treatment, and prevention (including masks and vaccines), along with future directions in these respective themes.
Areas of specific interest include:
- The natural course of COVID-19 infection along with outcome-based tools to classify the severity of infections.
- Prognostic indicators of the progression of mild–moderate COVID-19 infection to severe infection and death.
- Therapeutic approaches to COVID-19 infection based on its severity, including outpatient versus inpatient settings.
- Prognostic indicators of morbidity and mortality in COVID-19 infection.
- Definition and pathogenesis of long COVID symptoms post COVID-19 infection.
- COVID-19 severity and mortality rates based on ethnicity, age, gender, socio-economic status, and geographic location.
- COVID-19 variants and their responses to vaccines.
- The impact and longevity of the immunogenic response of vaccines in various patient populations.
This Special Issue reflects the unprecedented unity of researchers that has been witnessed globally in the face of a common threat to humanity and aims to feature the brightest discoveries in this field.
Prof. Dr. Ahmed O. Kaseb
Dr. Hassan Bencheqroun
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19 infection
- COVID antiviral
- SARS antigen test
- SARS RT-PCR
- COVID-19 treatment
- vaccination
- long COVID
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.